Merck & Co., Inc. (ETR:6MK)

Market Cap	230.37B -5.9%
Revenue (ttm)	54.75B +1.7%
Net Income	16.22B +56.7%
EPS	6.44 +58.1%
Shares Out	n/a
PE Ratio	14.20
Forward PE	21.70
Dividend	2.86 (3.12%)
Ex-Dividend Date	Dec 15, 2025

Volume	3,054
Average Volume	2,816
Open	90.40
Previous Close	91.40
Day's Range	90.30 - 91.80
52-Week Range	65.50 - 97.20
Beta	0.30
RSI	52.88
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: 6MK

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD